Roche (OTCMKTS:RHHBY) Downgraded to “Neutral” at Bank of America

Bank of America downgraded shares of Roche (OTCMKTS:RHHBY) from a buy rating to a neutral rating in a research note published on Thursday, Marketbeat reports.

Separately, HSBC began coverage on shares of Roche in a report on Friday, July 14th. They set a buy rating on the stock. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average target price of $193.75.

Roche Stock Performance

RHHBY stock opened at $36.63 on Thursday. Roche has a 52 week low of $34.70 and a 52 week high of $43.32. The company’s 50-day moving average price is $37.99 and its 200 day moving average price is $38.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.24 and a quick ratio of 0.93.

Institutional Trading of Roche

Several institutional investors and hedge funds have recently modified their holdings of RHHBY. Comerica Bank purchased a new position in shares of Roche during the second quarter valued at approximately $4,198,000. Vestor Capital LLC purchased a new position in shares of Roche during the second quarter valued at approximately $44,000. John G Ullman & Associates Inc. lifted its stake in shares of Roche by 19.5% during the second quarter. John G Ullman & Associates Inc. now owns 15,950 shares of the company’s stock valued at $609,000 after buying an additional 2,600 shares during the period. Principal Street Partners LLC lifted its stake in shares of Roche by 10.7% during the second quarter. Principal Street Partners LLC now owns 8,555 shares of the company’s stock valued at $327,000 after buying an additional 824 shares during the period. Finally, Cullen Capital Management LLC lifted its stake in shares of Roche by 3.4% during the second quarter. Cullen Capital Management LLC now owns 1,152,496 shares of the company’s stock valued at $44,025,000 after buying an additional 38,115 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation.